Literature DB >> 21666735

Pharmacogenomics: playing the odds.

Amy Maxmen.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21666735     DOI： 10.1038/474S9a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  6 in total

1.  ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

Authors:  Jacques Fellay; Alexander J Thompson; Dongliang Ge; Curtis E Gumbs; Thomas J Urban; Kevin V Shianna; Latasha D Little; Ping Qiu; Arthur H Bertelsen; Mark Watson; Amelia Warner; Andrew J Muir; Clifford Brass; Janice Albrecht; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2010-02-21       Impact factor: 49.962

2.  Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV.

Authors:  Armanda Casrouge; Jérémie Decalf; Mina Ahloulay; Cyril Lababidi; Hala Mansour; Anaïs Vallet-Pichard; Vincent Mallet; Estelle Mottez; James Mapes; Arnaud Fontanet; Stanislas Pol; Matthew L Albert
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

3.  Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function.

Authors:  Yuki Hitomi; Elizabeth T Cirulli; Jacques Fellay; John G McHutchison; Alexander J Thompson; Curtis E Gumbs; Kevin V Shianna; Thomas J Urban; David B Goldstein
Journal:  Gastroenterology       Date:  2011-01-01       Impact factor: 22.682

4.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

5.  Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yasuhito Tanaka; Nao Nishida; Masaya Sugiyama; Masayuki Kurosaki; Kentaro Matsuura; Naoya Sakamoto; Mina Nakagawa; Masaaki Korenaga; Keisuke Hino; Shuhei Hige; Yoshito Ito; Eiji Mita; Eiji Tanaka; Satoshi Mochida; Yoshikazu Murawaki; Masao Honda; Akito Sakai; Yoichi Hiasa; Shuhei Nishiguchi; Asako Koike; Isao Sakaida; Masatoshi Imamura; Kiyoaki Ito; Koji Yano; Naohiko Masaki; Fuminaka Sugauchi; Namiki Izumi; Katsushi Tokunaga; Masashi Mizokami
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

6.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330
  6 in total
  1 in total

1.  Editorial: Improving cancer chemotherapy through pharmacogenomics: a research topic.

Authors:  Luis A Quiñones; Kuen S Lee
Journal:  Front Genet       Date:  2015-06-03       Impact factor: 4.599
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.